Get started
Author

Michael B. Steele

Observed names: Michael B Steele, Michael Steele
OpenAlex ID: A5079277994
Induction of antiviral genes by the tumor microenvironment confers resistance to virotherapy
2013 · Yu-Ping Liu, Lukkana Suksanpaisan, et al. · Scientific Reports · 68
PDF
Safety Studies in Tumor and Non-Tumor-Bearing Mice in Support of Clinical Trials Using Oncolytic VSV-IFNβ-NIS
2016 · Lianwen Zhang, Michael B. Steele, et al. · Human Gene Therapy Clinical Development · 66
Comparative Oncology Evaluation of Intravenous Recombinant Oncolytic Vesicular Stomatitis Virus Therapy in Spontaneous Canine Cancer
2017 · Shruthi Naik, Gina D. Galyon, et al. · Molecular Cancer Therapeutics · 64
Perfusion Pressure Is a Critical Determinant of the Intratumoral Extravasation of Oncolytic Viruses
2015 · Amber Miller, Rebecca Nace, et al. · Molecular Therapy · 38
Mathematical Model for Radial Expansion and Conflation of Intratumoral Infectious Centers Predicts Curative Oncolytic Virotherapy Parameters
2013 · Kent Bailey, Amber Kirk, et al. · PLoS ONE · 31
PDF
Oncolytic measles and vesicular stomatitis virotherapy for endometrial cancer
2013 · Yu-Ping Liu, Michael B. Steele, et al. · Gynecologic Oncology · 29
Robust Oncolytic Virotherapy Induces Tumor Lysis Syndrome and Associated Toxicities in the MPC-11 Plasmacytoma Model
2016 · Lianwen Zhang, Michael B Steele, et al. · Molecular Therapy · 25
Oncolytic Virus with Attributes of Vesicular Stomatitis Virus and Measles Virus in Hepatobiliary and Pancreatic Cancers
2020 · Bolni Marius Nagalo, Camilo Ayala Breton, et al. · Molecular Therapy — Oncolytics · 22
Preclinical safety assessment of MV-s-NAP, a novel oncolytic measles virus strain armed with an H. pylori immunostimulatory bacterial transgene
2022 · Kimberly B. Viker, Michael B. Steele, et al. · Molecular Therapy — Methods & Clinical Development · 21
Pericarditis, Thymic Hyperplasia, and Graves' Thyrotoxicosis: Case Report and Review of the Literature
2013 · Peter S. Airel, Michael B. Steele, et al. · Military Medicine · 13
Preclinical Development of Oncolytic Immunovirotherapy for Treatment of HPVPOS Cancers
2018 · Lukkana Suksanpaisan, Rong Xu, et al. · Molecular Therapy — Oncolytics · 12
PDF
Safety Study: Intraventricular Injection of a Modified Oncolytic Measles Virus into Measles-Immune, hCD46-Transgenic, IFNαRko Mice
2016 · Sangeet Lal, Kah-Whye Peng, et al. · Human Gene Therapy Clinical Development · 7
74. The Mechanism of Hepatotoxicity from IV Administration of High Dose VSV
2015 · Lianwen Zhang, Michael Steele, et al. · Molecular Therapy · 1
PDF
Endothelial injury is a central driver of systemic IFN-β toxicity and is reversible through Jak inhibition
2026 · Lianwen Zhang, Linh Pham, et al. · Molecular Therapy Oncology
Supplemental Figure 2 from Comparative Oncology Evaluation of Intravenous Recombinant Oncolytic Vesicular Stomatitis Virus Therapy in Spontaneous Canine Cancer
2023 · Shruthi Naik, Gina D. Galyon, et al.
PDF
Supplemental Figure 1 from Comparative Oncology Evaluation of Intravenous Recombinant Oncolytic Vesicular Stomatitis Virus Therapy in Spontaneous Canine Cancer
2023 · Shruthi Naik, Gina D. Galyon, et al.
Supplemental Table 2 from Comparative Oncology Evaluation of Intravenous Recombinant Oncolytic Vesicular Stomatitis Virus Therapy in Spontaneous Canine Cancer
2023 · Shruthi Naik, Gina D. Galyon, et al.
Supplementary Table 1 from Comparative Oncology Evaluation of Intravenous Recombinant Oncolytic Vesicular Stomatitis Virus Therapy in Spontaneous Canine Cancer
2023 · Shruthi Naik, Gina D. Galyon, et al.
Supplemental Figure 3 from Comparative Oncology Evaluation of Intravenous Recombinant Oncolytic Vesicular Stomatitis Virus Therapy in Spontaneous Canine Cancer
2023 · Shruthi Naik, Gina D. Galyon, et al.
PDF
Supplementary Figure Legends from Comparative Oncology Evaluation of Intravenous Recombinant Oncolytic Vesicular Stomatitis Virus Therapy in Spontaneous Canine Cancer
2023 · Shruthi Naik, Gina D. Galyon, et al.
Supplementary Figure Legends from Comparative Oncology Evaluation of Intravenous Recombinant Oncolytic Vesicular Stomatitis Virus Therapy in Spontaneous Canine Cancer
2023 · Shruthi Naik, Gina D. Galyon, et al.
Supplemental Table 2 from Comparative Oncology Evaluation of Intravenous Recombinant Oncolytic Vesicular Stomatitis Virus Therapy in Spontaneous Canine Cancer
2023 · Shruthi Naik, Gina D. Galyon, et al.
Supplementary Table 1 from Comparative Oncology Evaluation of Intravenous Recombinant Oncolytic Vesicular Stomatitis Virus Therapy in Spontaneous Canine Cancer
2023 · Shruthi Naik, Gina D. Galyon, et al.
Supplemental Figure 1 from Comparative Oncology Evaluation of Intravenous Recombinant Oncolytic Vesicular Stomatitis Virus Therapy in Spontaneous Canine Cancer
2023 · Shruthi Naik, Gina D. Galyon, et al.
Supplemental Figure 2 from Comparative Oncology Evaluation of Intravenous Recombinant Oncolytic Vesicular Stomatitis Virus Therapy in Spontaneous Canine Cancer
2023 · Shruthi Naik, Gina D. Galyon, et al.
Works count: 29
Citation count: 397
H-index: 11
I10-index: 11
Year
Topic
Type